NCT04669899: Study of JTX 8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic Antibody, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with prior infusion of JTX-8064, LILRB2, or Immunoglobulin-like Transcript 4 (ILT4)-directed therapy; Patients with unstable, symptomatic, uncontrolled brain metastases- see trial for details; Patients with leptomeningeal disease

Comments are closed.

Up ↑